Skip to contentA
Abbott Laboratories
A
ABTAbbott Laboratories Q4 2025 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$11.46B$11.46Bderived+4.4% vs Q4 2024 Net Income$1.78B$1.78Bderived−80.8% vs Q4 2024 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Abbott Laboratories · CIK 1800 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Operating Incomederived$2,251,000,000+17.8% Operating Cash Flowderived$3,315,000,000+15.6% Free Cash Flowderived$2,626,000,000+22.3% Margins · derivedOperating margin19.6%+2.2 pt vs Q4 2024
Net margin15.5%−68.6 pt vs Q4 2024
ended Dec 31, 2025 · filed Feb 20, 2026 · 51 d after period end